[go: up one dir, main page]

AR067047A1 - Formulaciones acuosas de acetaminofen para inyeccion. - Google Patents

Formulaciones acuosas de acetaminofen para inyeccion.

Info

Publication number
AR067047A1
AR067047A1 ARP080102596A ARP080102596A AR067047A1 AR 067047 A1 AR067047 A1 AR 067047A1 AR P080102596 A ARP080102596 A AR P080102596A AR P080102596 A ARP080102596 A AR P080102596A AR 067047 A1 AR067047 A1 AR 067047A1
Authority
AR
Argentina
Prior art keywords
injection
acetaminofen
sodium bicarbonate
added
acetaminophen
Prior art date
Application number
ARP080102596A
Other languages
English (en)
Inventor
Lloret Sergio Perez
Pena Agnes Fernandez
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR067047A1 publication Critical patent/AR067047A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1:Una formulacion acuosa estable de acetaminofén para inyeccion, caracterizada porque comprende: a) entre aproximadamente 200,0 mg y aproximadamente 1.400,0 mg de acetaminofén; b) entre aproximadamente 200,0 mg y aproximadamente 10.000,0 mg de manitol para inyeccion; c) entre aproximadamente 0,0 mg y aproximadamente 30,0 mg de fosfato de sodio monobásico; d) entre aproximadamente 0,0 mg y aproximadamente 300,0 mg de povidona; e) entre aproximadamente 2,0 mg y aproximadamente 100,0 mg de L-cisteína, f) una cantidad suficiente de bicarbonato de sodio que se agrega durante la síntesis para ajustar el pH por encima de 8,0; g) luego, se agrega una cantidad suficiente de ácido cítrico luego del bicarbonato de sodio con el objetivo de disminuir el pH hasta entre aproximadamente 6,0 y aproximadamente 40; y h) un volumen de agua para inyeccion hasta un volumen de aproximadamente 100 mL; en donde el mencionado ácido cítrico se agrega luego de la adicion del mencionado bicarbonato de sodio.
ARP080102596A 2007-06-18 2008-06-18 Formulaciones acuosas de acetaminofen para inyeccion. AR067047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92919307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
AR067047A1 true AR067047A1 (es) 2009-09-30

Family

ID=40785551

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102596A AR067047A1 (es) 2007-06-18 2008-06-18 Formulaciones acuosas de acetaminofen para inyeccion.

Country Status (2)

Country Link
AR (1) AR067047A1 (es)
WO (1) WO2009081283A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404748B2 (en) 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
EP2464332B2 (en) 2009-08-13 2025-10-15 Neogen N.V. Method for producing a storage-stable formulation of paracetamol in aqueous solution
US9089477B2 (en) 2011-02-10 2015-07-28 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
ES2414557B1 (es) 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EE200400094A (et) * 2001-12-18 2004-08-16 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratoires S.A. Paratsetamooli parenteraalne kompositsioon
FR2851164B1 (fr) * 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions

Also Published As

Publication number Publication date
WO2009081283A2 (en) 2009-07-02
WO2009081283A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
UY27320A1 (es) Nuevas composiciones farmacéuticas
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
NZ598839A (en) Stabilized liquid and lyophilized adamts13 formulations
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR068598A1 (es) Composicion de cuidado oral de fluoruro que forma espuma
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
AR081870A1 (es) Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo
AR074541A1 (es) Composiciones desinfectantes de plata naturales
PE20070437A1 (es) FORMULACION ACUOSA hFSH
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
AR067047A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
SE9903831D0 (sv) Formulation of substituted benzimidazoles
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
AR111166A1 (es) Uso intradialítico de nitrito de sodio

Legal Events

Date Code Title Description
FB Suspension of granting procedure